Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Reduced Doses of Factor Concentrates and Bypassing Agents to Treat Breakthrough Bleeds in Patients with Hemophilia A and B on Fitusiran Antithrombin-Based Dosing Regimen: ATLAS-OLE

Steven W. Pipe, Kaan Kavakli, Tadashi Matsushita, Huyen Tran, Bulent Zulfikar, Laurel Menapace, Marja Puurunen, Wenruo Hu, Yuqian Shen, Chanchala Kaddi, Vanessa Salinas

Blood (2024) 144 (Supplement 1): 128.

https://doi.org/10.1182/blood-2024-206946

Published: 2024

Journal Articles

Clinical Outcomes over 2 Years of Once-Weekly Efanesoctocog Alfa Treatment in Children with Severe Hemophilia A: Second Interim Analysis from the Phase 3 XTEND-ed Long-Term Extension Study

Lynn Malec, Beatrice Nolan, Anthony K C Chan, Manuela Albisetti, Sheng-Chieh Chou, Bulent Zulfikar, Mindy Simpson, Liqi Feng, Helena Palmborg, Graham Neill, Lydia Abad-Franch, Sriya Gunawardena, Karin Fijnvandraat

Blood (2024) 144 (Supplement 1): 5495.

https://doi.org/10.1182/blood-2024-206915

Published: 2024

Journal Articles

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Blood (2024) 143 (22): 2256–2269.

https://doi.org/10.1182/blood.2023021864

Published: 2024

Includes: Supplemental data

Journal Articles

Treatment of Bleeding Episodes with Efanesoctocog Alfa in Children with Severe Hemophilia A in the XTEND-Kids Phase 3 Study

Lynn Malec, Amy Dunn, Manuel Carcao, Bulent Zulfikar, Ruben Berrueco, Simon Brown, Umer Khan, Sriya Gunawardena, Graham Neill, Lydia Abad-Franch, Linda Bystrická, Elena Santagostino, Sophie Susen

Blood (2023) 142 (Supplement 1): 3993.

https://doi.org/10.1182/blood-2023-188739

Published: 2023

Journal Articles

Treatment Burden and Patient Preference in Patients with Hemophilia A or B with Inhibitors on Concizumab Prophylaxis: Results from the Phase 3 explorer7 Study

Kingsley Hampton, Paul Knoebl, Jan Odgaard-Jensen, Oleksandra Stasyshyn, Jay Jay Thaung Zaw, Jesper Skov Neergaard, Bulent Zulfikar

Blood (2022) 140 (Supplement 1): 5591–5592.

https://doi.org/10.1182/blood-2022-163468

Published: 2022

Journal Articles

Prediction of Anti-FVIII Inhibitor Persistence By Anti-FVIII IgG Subclasses in Patients with Severe Hemophilia — A in the Sippet Cohort Study

Flora Peyvandi, MD PhD, Paolo Bucciarelli, MD, Carla Valsecchi, BSc, Marco Boscarino, Roberta Palla, PhD, Elena Santagostino, Amal El-Beshlawy, Mohsen Saleh Elalfy, MD, Vijay M. Ramanan, MBBS,MDDM, Peyman Eshghi, MD, Suresh Hanagavadi, MD, Mehran Karimi, MD, Cecil Ross, MD, Mamta V Manglani, MD, Guy Young, Tulika Seth, MDMBBS,FAAP, Shashikant Apte, MD FRCPA, Dinesh M Nayak, MD, Maria Elisa Mancuso, Johnny Mahlangu, Bonanad Santiago, MD, Monica H Cerqueira, MD PhD, Nadia P Ewing, MD, Christoph Male, MD, Tarek Owaidah, MDFRCPA, Veronica Soto Arellano, MD, Suvankar Majumdar, MBCHB, Mindy Simpson, MD, Mathew Thomas, MD, Ezio Zanon, Marilyn J Manco-Johnson, MD, Monica Martinez, MD, Maria Gabriella Mazzucconi, MD, Daniela Neme, MD, Rogelio Alejandro Paredes-Aguilera, MD, Alessandra N L Prezotti, MD MSc, Klaus Schmitt, MD, Bulent Zulfikar, Prof, Pier Mannuccio Mannucci, MD, Frits Richard Rosendaal, MD

Blood (2018) 132 (Supplement 1): 384.

https://doi.org/10.1182/blood-2018-99-114599

Published: 2018

Journal Articles

Good Care and Long-Term Follow-up in Young Hemophiliacs

Zeynep Iscan, MD, Basak Koc, MD, Onder Kilicoglu, Prof, Ata Atalar, Prof, Omer Taser, Prof, Gulten Cetik, Bulent Zulfikar, Prof

Blood (2018) 132 (Supplement 1): 5028.

https://doi.org/10.1182/blood-2018-99-117936

Published: 2018

Journal Articles

Follow-up and Treatment Expectancy and Compliance of Y-Generation Hemophiliacs

Bulent Zulfikar, Prof, Basak Koc, MD, Yusuf Buyukpinarbasili, Fikret Bezgal, Caner Dadak, Funda Ciga, Irmak Gumustas, Haluk Zulfikar

Blood (2018) 132 (Supplement 1): 5029.

https://doi.org/10.1182/blood-2018-99-117901

Published: 2018

Journal Articles

Metabolic and Endocrin Complications of Pediatric, Adolescent and Young Adult Acute Lymphoblastic Leukemia: Single Centre Experience

Bulent Zulfikar, Prof, Basak Koc, MD, Pınar Ozturk, MD

Blood (2017) 130 (Supplement 1): 5009.

https://doi.org/10.1182/blood.V130.Suppl_1.5009.5009

Published: 2017

Journal Articles

Immun Tolerance Induction in Hemophilia with Inhibitors: Istanbul Experience

Basak Koc, MD, Bulent Zulfikar, Prof, Gul Nihal Ozdemir, MD

Blood (2017) 130 (Supplement 1): 4890.

https://doi.org/10.1182/blood.V130.Suppl_1.4890.4890

Published: 2017

Journal Articles

Risk Adapted Treatment in Childhood Hodgkin's Lymphoma: Outcome and Changing Epidemiologic Features in 25 Years

Rejin Kebudi, MD Prof, Sema Bay Buyukkapu, MD, Omer Gorgun, MD, Fulya Yaman Agaoglu, MD, Bulent Zulfikar, MD, Inci Ayan, MD, Ayca Iribas, MD, Dizdar Yavuz, MD, Oner Dogan, MD, Emin Darendeliler, MD

Blood (2016) 128 (22): 4158.

https://doi.org/10.1182/blood.V128.22.4158.4158

Published: 2016

Journal Articles

Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study

Flora Peyvandi, MD PhD, Pier Mannuccio Mannucci, MD, Isabella Garagiola, PhD, Mohsen Elalfy, MD, Amal El-Beshlawy, MD, Madatha V. Ramanan, MD, Peyman Eshghi, MD, Suresh Hanagavadi, Ramabadran Varadarajan, MD, Mehran Karimi, MD, Mamta V. Manglani, MD, Cecil Ross, MD, Guy Young, MD, Tulika Seth, MD, Shashikant Apte, MD FRCPA, Dinesh M. Nayak, MD, Adriana C. Sandoval Gonzales, MD, Elena Santagostino, MD PhD, Maria Elisa Mancuso, MD PhD, Johnny N. Mahlangu, MD, Santiago Bonanad, PhD, Monica Cerqueira, MD, Nadia P. Ewing, MD, Christoph Male, MD MSC, Tarek Owaidah, MD FRCPA, Veronica Soto Arellano, MD, Nathan L. Kobrinsky, MD FRCP, Suvankar Majumdar, MD, Rosario Perez Garrido, MD, Anupam Sachdeva, Mindy Simpson, MD FAAP, Mathew Thomas, Ezio Zanon, MD, ALI Bulent Antmen, Kaan Kavakli, MD, Marilyn Manco-Johnson, MD, Monica Martinez, MD, Esperanza Marzouka, MS, PS, Maria Gabriella Mazzucconi, MD, Daniela Neme, MD, Angeles Palomo Bravo, MD, Rogelio Paredes Aguilera, MD, Alessandra Nunes Loureiro Prezotti, MD, Schmitt Klaus, MD, Brian M. Wicklund, MD MPH, Bulent Zulfikar, MD, Rosendaal R. Frits, MD PhD

Blood (2015) 126 (23): 5.

https://doi.org/10.1182/blood.V126.23.5.5

Published: 2015

Journal Articles

Prophylactic Dosing of Anti-Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors: Results of the Pro-FEIBA Study

Cindy A. Leissinger, MD, Eric Berntorp, MD, Chiara Biasioli, MD, Shannon Carpenter, MD, MS, Hyejin Jo, MS, Kaan Kavakli, MD, Claude Negrier, MD, Angiola Rocino, MD, Jerzy Windyga, MD, Bulent Zulfikar, MD, Alessandro Gringeri, MD

Blood (2010) 116 (21): 720.

https://doi.org/10.1182/blood.V116.21.720.720

Published: 2010

NARROW

Reduced Doses of Factor Concentrates and Bypassing Agents to Treat Breakthrough Bleeds in Patients with Hemophilia A and B on Fitusiran Antithrombin-Based Dosing Regimen: ATLAS-OLE

Clinical Outcomes over 2 Years of Once-Weekly Efanesoctocog Alfa Treatment in Children with Severe Hemophilia A: Second Interim Analysis from the Phase 3 XTEND-ed Long-Term Extension Study

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Treatment of Bleeding Episodes with Efanesoctocog Alfa in Children with Severe Hemophilia A in the XTEND-Kids Phase 3 Study

Treatment Burden and Patient Preference in Patients with Hemophilia A or B with Inhibitors on Concizumab Prophylaxis: Results from the Phase 3 explorer7 Study

Prediction of Anti-FVIII Inhibitor Persistence By Anti-FVIII IgG Subclasses in Patients with Severe Hemophilia — A in the Sippet Cohort Study

Good Care and Long-Term Follow-up in Young Hemophiliacs

Follow-up and Treatment Expectancy and Compliance of Y-Generation Hemophiliacs

Metabolic and Endocrin Complications of Pediatric, Adolescent and Young Adult Acute Lymphoblastic Leukemia: Single Centre Experience

Immun Tolerance Induction in Hemophilia with Inhibitors: Istanbul Experience

Risk Adapted Treatment in Childhood Hodgkin's Lymphoma: Outcome and Changing Epidemiologic Features in 25 Years

Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study

Prophylactic Dosing of Anti-Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors: Results of the Pro-FEIBA Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only